Literature DB >> 16424154

The central role of the alternative complement pathway in human disease.

Joshua M Thurman1, V Michael Holers.   

Abstract

The complement system is increasingly recognized as important in the pathogenesis of tissue injury in vivo following immune, ischemic, or infectious insults. Within the complement system, three pathways are capable of initiating the processes that result in C3 activation: classical, alternative, and lectin. Although the roles that proinflammatory peptides and complexes generated during complement activation play in mediating disease processes have been studied extensively, the relative contributions of the three activating pathways is less well understood. Herein we examine recent evidence that the alternative complement pathway plays a key and, in most instances, obligate role in generating proinflammatory complement activation products in vivo. In addition, we discuss new concepts regarding the mechanisms by which the alternative pathway is activated in vivo, as recent clinical findings and experimental results have provided evidence that continuous active control of this pathway is necessary to prevent unintended targeting and injury to self tissues.

Entities:  

Mesh:

Year:  2006        PMID: 16424154     DOI: 10.4049/jimmunol.176.3.1305

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  173 in total

1.  The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Talat H Malik; Andrea Cortini; Daniele Carassiti; Joseph J Boyle; Dorian O Haskard; Marina Botto
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

2.  Plasminogen is a complement inhibitor.

Authors:  Diana Barthel; Susann Schindler; Peter F Zipfel
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

3.  Targeted modulation of the neuroinflammatory response after spinal cord injury: the ongoing quest for the "holy grail".

Authors:  Philip F Stahel; Michael A Flierl
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

4.  Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

Authors:  Henry F Edelhauser; Cheryl L Rowe-Rendleman; Michael R Robinson; Daniel G Dawson; Gerald J Chader; Hans E Grossniklaus; Kay D Rittenhouse; Clive G Wilson; David A Weber; Baruch D Kuppermann; Karl G Csaky; Timothy W Olsen; Uday B Kompella; V Michael Holers; Gregory S Hageman; Brian C Gilger; Peter A Campochiaro; Scott M Whitcup; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-11       Impact factor: 4.799

5.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 6.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

7.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

Review 8.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

9.  Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/reperfusion injury.

Authors:  Haekyung Lee; Danielle J Green; Lawrence Lai; Yunfang Joan Hou; Jens C Jensenius; David Liu; Cheolho Cheong; Chae Gyu Park; Ming Zhang
Journal:  Mol Immunol       Date:  2009-12-09       Impact factor: 4.407

10.  Evidence for non-traditional activation of complement factor C3 during murine liver regeneration.

Authors:  Amelia Clark; Alexander Weymann; Eric Hartman; Yumirle Turmelle; Michael Carroll; Joshua M Thurman; V Michael Holers; Dennis E Hourcade; David A Rudnick
Journal:  Mol Immunol       Date:  2008-05-01       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.